|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Slovenia
Espicom Business Intelligence Ltd, Oct 2011, Pages: 64
THE PHARMACEUTICAL MARKET: SLOVENIA - REVIEW
In per capita terms, Slovenia is the richest country in Central & Eastern Europe (CEE), with spending per head at least double that found elsewhere in the former Communist countries of the region. Although the economy contracted in 2009, for the first time in 16 years, economic growth returned in 2010 and the economy is set to increase between 2012 and 2016. Slovenia also spends one of the highest proportions of GDP on health than any other CEE country. Over two-thirds of funding is channelled through the compulsory health insurance system. Out-of-pocket payments account for less than half of private spending; this is less than the figure throughout the rest of the region.
In per capita terms, the Slovenian pharmaceutical market is twice the size of Latvia and the highest in the region. The market is predicted to expand in US dollar terms over the next few years, although this may be tempered by slow economic growth in 2011. OTC growth has been steady in recent years. Cough & cold products represent the largest OTC category. Generics account for around a large proportion of the pharmaceutical market in value terms but in volume terms it is much higher. The country’s patent laws have traditionally allowed Slovenia’s manufacturers great leeway in copying products under patent in the West and pharmacists are allowed to practice generic substitution.
Both Krka and Lek play a major role in the Slovenian market and those of Eastern Europe. They are also seeking to expand their presence in the USA and in the emerging EU generics markets. Lek has had better success in Western markets since 2002, due largely to the Novartis buy-out, and now appears to be pulling significantly ahead of its rival. Multinationals tend not to have manufacturing plants in Slovenia, given the country's small size and proximity to the major Western European manufacturing centres. Bayer is one long-standing exception, having had a joint venture with Lek since the early 1970s.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Customers who bought this item also bought
The Pharmaceutical Market: Croatia
The Pharmaceutical Market: Slovakia
The Pharmaceutical Market: Estonia
The Pharmaceutical Market: Latvia
The Pharmaceutical Market: Pakistan
The Pharmaceutical Market: Canada
The Pharmaceutical Market: Australia
The Pharmaceutical Market: Turkey
The Pharmaceutical Market: Czech Republic
The Pharmaceutical Market: Bulgaria
|
|
|
|
